Hiemke C, Banger M, Ghraf R, Knuppen R
J Steroid Biochem. 1983 Oct;19(4):1469-74. doi: 10.1016/0022-4731(83)91122-6.
Using a competitive binding assay the effects of 2-hydroxyestradiol-17 beta, 4-hydroxyestradiol-17 beta, estradiol-17 beta and progesterone on the binding of tritiated catecholaminergic ligands to membrane preparations from rat brain and pituitary gland were studied. Up to a concentration of 10(-5) M none of the steroids tested was able to displace [3H]spiroperidol, [3H]dihydroergocryptine or [3H]dihydroalprenolol. The data suggest that the catecholestrogens do not interfere directly with the binding of catecholaminergic ligands to dopaminergic, alpha-adrenergic or beta-adrenergic receptors in the central nervous system. The view that a catechol structure is not essential for the interaction with dopaminergic receptors was further supported by the results obtained from additional studies on the competition of O-methylated and deaminated dopamine metabolites with [3H]spiroperidol binding.
采用竞争性结合试验,研究了2-羟基雌二醇-17β、4-羟基雌二醇-17β、雌二醇-17β和孕酮对氚标记的儿茶酚胺能配体与大鼠脑和垂体膜制剂结合的影响。在所测试的类固醇中,浓度高达10^(-5) M时,没有一种能够取代[3H]螺哌啶醇、[3H]二氢麦角隐亭或[3H]二氢烯丙洛尔。数据表明,儿茶酚雌激素不会直接干扰儿茶酚胺能配体与中枢神经系统中多巴胺能、α-肾上腺素能或β-肾上腺素能受体的结合。对O-甲基化和脱氨基多巴胺代谢物与[3H]螺哌啶醇结合竞争的进一步研究结果,进一步支持了儿茶酚结构对于与多巴胺能受体相互作用并非必不可少的观点。